the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a single-arm,open, multicenter, phase II clinical study of the efficacy and safety of
human anti-PD-L1 monoclonal antibody Injection (LDP) in the treatment of urinary and male
genital tumors.